WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics ®, a clinical-stage biopharmaceutical company, today announced positive data from the STARLYNG-1 (LYN-005-C-301) study, comparing the ...
Topline results of the Phase 1b/2a study were presented during a poster session at the 2023 Neuroscience Education Institute (NEI) Congress Delpor's drug/device combination risperidone implant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback